Compare Citius Pharmaceuticals Inc (CTXR) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Waste Management, Inc. trades at $207.86 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 6165.9× Citius Pharmaceuticals Inc's market cap, and Waste Management, Inc. pays a 1.8% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Waste Management, Inc. for 130 Days on average.
| CTXR | WM | |
|---|---|---|
Market Cap | $13.62M | $83.98B |
Volume | 132,438 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $1.82 | $246.51 |
52-Week Low | $0.48 | $196.77 |
Typical Hold Time | 17 Days | 130 Days |
Enterprise Value | $3.79M | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Waste Management (WM) trades at $207.71, down 0.59% on the day, with a bullish technical signal despite bearish moving averages. The company reported revenue of $25.20 billion in 2025, with net income of $2.71 billion and a net margin of 10.74%. Recent earnings show mixed results, with a miss in Q4 2025 but beats in Q1 and Q2 2026. Analyst consensus is strongly positive with 54.29% buy ratings and no sell recommendations.
WM's outlook remains favorable due to steady revenue growth, strong cash flow, and a resilient business model. Key risks include elevated debt levels and competitive pressures. The stock offers a reliable dividend, with the next payment of $0.95 scheduled for September 25, 2026. Investors should weigh solid fundamentals against debt concerns for long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
